

References for the Final Rule

Use of Ozone-Depleting Substances; Removal of Essential-Use Designations

Docket No. 2003P-0029

1. U.S. Food and Drug Administration, "Guidance for Industry: Integration of Dose-Counting Mechanisms into MDI Drug Products," March 2003.
2. Penick, T.B. et al., "Accuracy of Float Testing for Metered-Dose Inhaler Canisters," *Journal of the American Pharmaceutical Association*, 42:582, July/August 2002.
3. Craig-McFeely, P.M. et al., "Prospective Observational Cohort Safety Study to Monitor the Introduction of a Non-CFC Formulation of Salbutamol with HFA 134a in England," *International Journal of Clinical Pharmacology and Therapeutics*, 41:67-76, 2003.
4. Goldman, D.P. et al., "Pharmacy Benefits and the Use of Drugs by the Chronically Ill," *The Journal of the American Medical Association*, May 19, 2004; 291:2344-2350, 2349.
5. United Nations Environmental Programme, "Production and Consumption of Ozone-Depleting Substances 1986-2000," 2002.
6. U.S. Environmental Protection Agency, "The Benefits and Costs of the Clean Air Act: 1990-2010," 1999 (<http://www.epa.gov/air/sect812/copy99.html>)
7. Mannino, D.M. et al., "Chronic Obstructive Pulmonary Disease Surveillance--United States, 1971-2000," *Morbidity and Mortality Weekly Report*, 51(SS06):1-16, August 2, 2002.

2003P-0029

BKG 2
1

8. American Lung Association, "Trends in Asthma Morbidity and Mortality," Epidemiology & Statistics Unit, Research and Scientific Affairs, April 2004.
9. Mannino, D.M. et al., "Surveillance for Asthma--United States, 1980-1999," Morbidity and Mortality Weekly Report, 51(SS01):1-13, March 29, 2002.
10. Analysis completed by FDA based on information provided by IMS Health, IMS National Prescription Audit™, 2004; IMS Health, IMS MIDAS™, Q1/2004--Q2/2004. These data can be purchased from IMS Health. Please send all inquiries to: IMS Health, Attn: Brian Palumbo, Account Manage, 660 W. Germantown Pike, Plymouth Meeting, PA 19462.
11. Rozek, R.P., and E.R. Bishko, "Economics Issues Raised in the FDA's Proposed Rule on Removing the Essential-Use Designation for Albuterol MDIs," National Economic Research Associates, August 13, 2004 (FDA Docket No. 2003P-0029/C25).
12. Agency for Healthcare Research and Quality, "Albuterol Inhalers: Prescriptions per User, Price per Prescription and Expenditure Given Use," spreadsheet prepared at FDA's request for this rulemaking, 2004.
13. Ringel, J.S. et al., "The Elasticity of Demand for Health Care," National Defense Research Institute, Rand Health, 2002.
14. U.S. Census Bureau, "Income, Poverty, and Health Insurance Coverage in the United States: 2003," Current Population Reports, U.S. Department of Commerce, August 2004, pp. 14-15.
15. Morelli, D., and M.R. Koenigsberg, "Sample Medication Dispensing in a Residency Practice," Journal of Family Practice, 34(1):42-48, 1992.

16. Peterson, M.C. et al., "Disposition of Pharmaceutical Samples from a Private Medical Clinic," *Journal of the American Pharmacists Association*, 44(3):397-398, 2004.

17. U.S. Department of Health & Human Services, "Guidance on Proper Consideration of Small Entities in Rulemakings of the U.S. Department of Health and Human Services," May 2003.

18. Congressional Budget Office, "How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry," July 1998.